
June 27 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:
BIOCRYST ANNOUNCES SALE OF EUROPEAN ORLADEYO® (BEROTRALSTAT) BUSINESS TO NEOPHARMED GENTILI FOR UP TO $264 MILLION
BIOCRYST PHARMACEUTICALS INC - NEOPHARMED GENTILI TO PAY BIOCRYST $250 MILLION UPFRONT FOR ORLADEYO
BIOCRYST PHARMACEUTICALS INC - EXPECTS TO END 2027 WITH $700 MILLION IN CASH
BIOCRYST PHARMACEUTICALS INC - TO USE PROCEEDS TO RETIRE ALL REMAINING TERM DEBT